The relationship of serotonin to depression in Parkinson's disease.
Identifieur interne : 003F40 ( Ncbi/Merge ); précédent : 003F39; suivant : 003F41The relationship of serotonin to depression in Parkinson's disease.
Auteurs : R. Mayeux [États-Unis] ; Y. Stern ; M. Sano ; J B Williams ; L J CoteSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1988.
English descriptors
- KwdEn :
- 5-Hydroxytryptophan (therapeutic use), Aged, Clinical Trials as Topic, Dementia (cerebrospinal fluid), Dementia (complications), Depressive Disorder (cerebrospinal fluid), Depressive Disorder (drug therapy), Depressive Disorder (etiology), Female, Humans, Hydroxyindoleacetic Acid (cerebrospinal fluid), Longitudinal Studies, Male, Middle Aged, Parkinson Disease (complications), Serotonin (physiology).
- MESH :
- chemical , cerebrospinal fluid : Hydroxyindoleacetic Acid.
- chemical , physiology : Serotonin.
- chemical , therapeutic use : 5-Hydroxytryptophan.
- cerebrospinal fluid : Dementia, Depressive Disorder.
- complications : Dementia, Parkinson Disease.
- drug therapy : Depressive Disorder.
- etiology : Depressive Disorder.
- Aged, Clinical Trials as Topic, Female, Humans, Longitudinal Studies, Male, Middle Aged.
Abstract
We have previously reported a correlation between depression in patients with idiopathic Parkinson's disease and decreased concentrations of the cerebrospinal fluid content of the serotonin metabolite, 5-HIAA. To further examine this relationship, we repeated the study in a new cohort of patients while they remained on dopaminergic medications, conducted follow-up interviews and examinations in our original cohort, and conducted an open trial of the serotonin precursor, 5-hydroxytryptophan in a group of new patients with depression. We were again able to demonstrate a significant reduction in cerebrospinal 5-HIAA in depressed patients in comparison to controls and patients without depression. Demented patients with Parkinson's disease, particularly those with concurrent depression, had the lowest values of 5-HIAA. No new cases of depression occurred in our original cohort after 2 1/2 years of follow-up, and depression remitted following conventional or experimental treatment in four patients. Depression improved in six of the seven new patients following oral 5-hydroxytryptophan. Three of these patients allowed a repeat lumbar puncture, and the concentration of 5-HIAA increased following 5-hydroxytryptophan. These three studies support our hypothesis that depression in idiopathic Parkinson's disease is associated with a reduction in brain serotonin. However, it also suggests that other factors, biological or environmental, may be causal factors.
DOI: 10.1002/mds.870030308
PubMed: 2461509
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 005054
- to stream PubMed, to step Curation: 005054
- to stream PubMed, to step Checkpoint: 005013
Links to Exploration step
pubmed:2461509Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The relationship of serotonin to depression in Parkinson's disease.</title><author><name sortKey="Mayeux, R" sort="Mayeux, R" uniqKey="Mayeux R" first="R" last="Mayeux">R. Mayeux</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York 10032.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York</wicri:cityArea></affiliation></author><author><name sortKey="Stern, Y" sort="Stern, Y" uniqKey="Stern Y" first="Y" last="Stern">Y. Stern</name></author><author><name sortKey="Sano, M" sort="Sano, M" uniqKey="Sano M" first="M" last="Sano">M. Sano</name></author><author><name sortKey="Williams, J B" sort="Williams, J B" uniqKey="Williams J" first="J B" last="Williams">J B Williams</name></author><author><name sortKey="Cote, L J" sort="Cote, L J" uniqKey="Cote L" first="L J" last="Cote">L J Cote</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1988">1988</date><idno type="RBID">pubmed:2461509</idno><idno type="pmid">2461509</idno><idno type="doi">10.1002/mds.870030308</idno><idno type="wicri:Area/PubMed/Corpus">005054</idno><idno type="wicri:Area/PubMed/Curation">005054</idno><idno type="wicri:Area/PubMed/Checkpoint">005013</idno><idno type="wicri:Area/Ncbi/Merge">003F40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The relationship of serotonin to depression in Parkinson's disease.</title><author><name sortKey="Mayeux, R" sort="Mayeux, R" uniqKey="Mayeux R" first="R" last="Mayeux">R. Mayeux</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York 10032.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York</wicri:cityArea></affiliation></author><author><name sortKey="Stern, Y" sort="Stern, Y" uniqKey="Stern Y" first="Y" last="Stern">Y. Stern</name></author><author><name sortKey="Sano, M" sort="Sano, M" uniqKey="Sano M" first="M" last="Sano">M. Sano</name></author><author><name sortKey="Williams, J B" sort="Williams, J B" uniqKey="Williams J" first="J B" last="Williams">J B Williams</name></author><author><name sortKey="Cote, L J" sort="Cote, L J" uniqKey="Cote L" first="L J" last="Cote">L J Cote</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1988" type="published">1988</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-Hydroxytryptophan (therapeutic use)</term><term>Aged</term><term>Clinical Trials as Topic</term><term>Dementia (cerebrospinal fluid)</term><term>Dementia (complications)</term><term>Depressive Disorder (cerebrospinal fluid)</term><term>Depressive Disorder (drug therapy)</term><term>Depressive Disorder (etiology)</term><term>Female</term><term>Humans</term><term>Hydroxyindoleacetic Acid (cerebrospinal fluid)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Serotonin (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Hydroxyindoleacetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Serotonin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>5-Hydroxytryptophan</term></keywords><keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Dementia</term><term>Depressive Disorder</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depressive Disorder</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Clinical Trials as Topic</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have previously reported a correlation between depression in patients with idiopathic Parkinson's disease and decreased concentrations of the cerebrospinal fluid content of the serotonin metabolite, 5-HIAA. To further examine this relationship, we repeated the study in a new cohort of patients while they remained on dopaminergic medications, conducted follow-up interviews and examinations in our original cohort, and conducted an open trial of the serotonin precursor, 5-hydroxytryptophan in a group of new patients with depression. We were again able to demonstrate a significant reduction in cerebrospinal 5-HIAA in depressed patients in comparison to controls and patients without depression. Demented patients with Parkinson's disease, particularly those with concurrent depression, had the lowest values of 5-HIAA. No new cases of depression occurred in our original cohort after 2 1/2 years of follow-up, and depression remitted following conventional or experimental treatment in four patients. Depression improved in six of the seven new patients following oral 5-hydroxytryptophan. Three of these patients allowed a repeat lumbar puncture, and the concentration of 5-HIAA increased following 5-hydroxytryptophan. These three studies support our hypothesis that depression in idiopathic Parkinson's disease is associated with a reduction in brain serotonin. However, it also suggests that other factors, biological or environmental, may be causal factors.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2461509</PMID><DateCreated><Year>1989</Year><Month>01</Month><Day>05</Day></DateCreated><DateCompleted><Year>1989</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>1988</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>The relationship of serotonin to depression in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>237-44</MedlinePgn></Pagination><Abstract><AbstractText>We have previously reported a correlation between depression in patients with idiopathic Parkinson's disease and decreased concentrations of the cerebrospinal fluid content of the serotonin metabolite, 5-HIAA. To further examine this relationship, we repeated the study in a new cohort of patients while they remained on dopaminergic medications, conducted follow-up interviews and examinations in our original cohort, and conducted an open trial of the serotonin precursor, 5-hydroxytryptophan in a group of new patients with depression. We were again able to demonstrate a significant reduction in cerebrospinal 5-HIAA in depressed patients in comparison to controls and patients without depression. Demented patients with Parkinson's disease, particularly those with concurrent depression, had the lowest values of 5-HIAA. No new cases of depression occurred in our original cohort after 2 1/2 years of follow-up, and depression remitted following conventional or experimental treatment in four patients. Depression improved in six of the seven new patients following oral 5-hydroxytryptophan. Three of these patients allowed a repeat lumbar puncture, and the concentration of 5-HIAA increased following 5-hydroxytryptophan. These three studies support our hypothesis that depression in idiopathic Parkinson's disease is associated with a reduction in brain serotonin. However, it also suggests that other factors, biological or environmental, may be causal factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York 10032.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Cote</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-02802</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR00645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>54-16-0</RegistryNumber><NameOfSubstance UI="D006897">Hydroxyindoleacetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>C1LJO185Q9</RegistryNumber><NameOfSubstance UI="D006916">5-Hydroxytryptophan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006916">5-Hydroxytryptophan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003704">Dementia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006897">Hydroxyindoleacetic Acid</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000134">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012701">Serotonin</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2461509</ArticleId><ArticleId IdType="doi">10.1002/mds.870030308</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Cote, L J" sort="Cote, L J" uniqKey="Cote L" first="L J" last="Cote">L J Cote</name><name sortKey="Sano, M" sort="Sano, M" uniqKey="Sano M" first="M" last="Sano">M. Sano</name><name sortKey="Stern, Y" sort="Stern, Y" uniqKey="Stern Y" first="Y" last="Stern">Y. Stern</name><name sortKey="Williams, J B" sort="Williams, J B" uniqKey="Williams J" first="J B" last="Williams">J B Williams</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Mayeux, R" sort="Mayeux, R" uniqKey="Mayeux R" first="R" last="Mayeux">R. Mayeux</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003F40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:2461509
|texte= The relationship of serotonin to depression in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:2461509" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |